Merrill Lynch analyst Travis Steed reiterated a Buy rating on Dexcom (NASDAQ:DXCM) on Monday, setting a price target of $500, which is approximately 43.61% above the present share price of $348.16.
Steed expects Dexcom to post earnings per share (EPS) of $0.75 for the fourth quarter of 2020.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Dexcom, with an average price target of $450.55.
The analysts price targets range from a high of $540 to a low of $350.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $500.9 million and a net profit of $94.1 million. The company's market cap is $33.42 billion.
According to TipRanks.com, Merrill Lynch analyst Travis Steed is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 33.7% and a 65.22% success rate.
DexCom , Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.